Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 13/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | TACR1 | P25103 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25605133 | 1.00 | HRH3 (0.41) | HRH3CYP3A4CYP2C19CYP2D6KCNH2 | |
| SCHEMBL25605129 | 1.00 | HRH3 (0.41) | HRH3CYP3A4CYP2C19CYP2D6KCNH2 | |
| SCHEMBL26295710 | 0.97 | HRH3 (0.43) | HRH3CYP3A4CYP2C19CYP2D6KCNH2 | |
| SCHEMBL23251605 | 0.90 | HRH3 (0.40) | HRH3CYP3A4CYP2C19CYP2D6KCNH2 | |
| SCHEMBL25630268 | 0.85 | KDM4E (0.47) | CYP3A4CYP2C19CYP2D6KCNH2KDM4E | |
| SCHEMBL25604746 | 0.85 | KDM4E (0.47) | CYP3A4CYP2C19CYP2D6KCNH2KDM4E | |
| SCHEMBL25600400 | 0.84 | HRH3 (0.48) | HRH3CYP3A4CYP2C19CYP2D6KCNH2 | |
| SCHEMBL25600401 | 0.84 | HRH3 (0.48) | HRH3CYP3A4CYP2C19CYP2D6KCNH2 | |
| SCHEMBL26295601 | 0.83 | HRH3 (0.39) | HRH3CYP2D6KCNH2 | |
| SCHEMBL25630569 | 0.83 | HRH3 (0.40) | HRH3CYP2D6KCNH2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230173078-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-06-08 | — | — | US | disclosed |
| WO-2023278402-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230173078-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCA2, SMARCC2 | HRH3 3548/4885CYP3A4 2211/4885CYP2C19 3201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.